Peptide Comparison
Dihexa vs Adamax
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Dihexa and Adamax share the nootropic class and carry roughly equivalent evidence (Preclinical + Anecdotal / Anecdotal). On the catalogued data layer Adamax has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Adamax's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Shared safety considerations
Both compounds share these reported concerns: very limited human data. Open each peptide page for the full risk paragraph and source citations.
Side-by-side
| Dihexa | Adamax | |
|---|---|---|
| Class | Angiotensin IV analog; HGF potentiator | Modified Semax analog (nootropic) |
| Drug class | Cognitive | Cognitive |
| Mechanism | Enhances HGF/c-Met signaling; promotes synaptogenesis and dendritic spine formation | Similar to Semax; BDNF/NGF upregulation; enhanced stability |
| Route | Oral / Transdermal | Intranasal |
| Half-life | ~10 hrs | ~minutes |
| Dosage (research) | 8-45 mg oral daily (anecdotal) | 200-600 mcg intranasal daily |
| Evidence tier | Preclinical + Anecdotal | Anecdotal |
| Research depth | 17 indexed | 6 indexed |
| Availability | Research Chemical | Research Chemical |
| Reported risks | Very limited human data; theoretical tumor risk via HGF pathway | Very limited human data |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Dihexa or Adamax?
Dihexa and Adamax share the nootropic class and carry roughly equivalent evidence (Preclinical + Anecdotal / Anecdotal). On the catalogued data layer Adamax has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Adamax's evidence base is currently denser.
What is the difference between Dihexa and Adamax?
Dihexa is classed as Angiotensin IV analog; HGF potentiator; Adamax is classed as Modified Semax analog (nootropic). Reported mechanism: Dihexa, Enhances HGF/c-Met signaling; promotes synaptogenesis and dendritic spine formation; Adamax, Similar to Semax; BDNF/NGF upregulation; enhanced stability. Reported half-life: Dihexa, ~10 hrs; Adamax, ~minutes. Routes in published studies: Dihexa, Oral / Transdermal; Adamax, Intranasal.
Which has stronger evidence, Dihexa or Adamax?
Adamax has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Dihexa is graded Preclinical + Anecdotal, with 2 cited sources on its reference page and 17 indexed studies. Adamax is graded Anecdotal, with 6 cited sources on its reference page and 6 indexed studies.
Which is more accessible, Dihexa or Adamax?
Neither Dihexa nor Adamax is an FDA-approved drug. Catalog status: Dihexa, Research Chemical; Adamax, Research Chemical. Dihexa's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn.
Are Dihexa and Adamax ever combined?
Dihexa and Adamax appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…